Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to... | May 12, 2023

Related Keywords

Sweden ,Gothenburg ,Vastra Gotalands Lan ,Australia ,Helsinki ,Eteläuomen Läi ,Finland ,Switzerland ,Swiss ,Matthias Alder ,C Evan Ballantyne ,Evan Ballantyne ,Gain Therapeutics Inc ,Company Annual Report On Form ,Exchange Commission On ,Silverstein Foundation For Parkinson ,Human Research Ethics Committee ,University Of Helsinki ,Institute For Research ,European Union Horizon ,International Conference On Alzheimer ,Nasdaq ,Exchange Commission ,Michaelj Fox Foundation For Parkinson Research ,Swiss Innovation Agency ,Gain Therapeutics ,Chief Financial Officer ,Chief Executive ,Cell Based Models ,Amyloid Beta ,Swiss Accelerator ,Newcells Biotech ,Months Ended March ,Silverstein Foundation ,Swiss Accelerator Innovation Project ,Private Securities Litigation Reform Act ,Annual Report ,Media Contact ,Nc Stock Exchange ,News ,Information ,Press Release ,Uccessfully ,Ompleted ,Help ,Toxicology ,Studies ,Or ,Head ,Program ,N ,Ba1 ,Iseasecompany ,Us ,Track ,O ,Ubmit ,Application ,Start ,F ,Hase , ,Linical ,Trial ,F Ganx Us36269b1052 ,